pabinafusp alfa

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Home
Ligands
pabinafusp alfa

GtoPdb Ligand ID: 11772

Synonyms: IZCARGO® | JR-141 | JR141

pabinafusp alfa is an approved drug (Japan (2021))

Compound class: Antibody

Comment: Pabinafusp (JR-141) is a fusion protein of the Fab domains of an anti-transferrin receptor monoclonal and the enzyme iduronate 2-sulfatase (IDS; P22304) [5], an enzyme that is deficient in patients with the lysosomal storage disease mucopolysaccharidosis type II (MPS II; Hunter syndrome) [1-2]. It is an intravenously administered enzyme replacement therapy. The anti-transferrin receptor component facilitates receptor-mediated movement of the fused enzyme across the blood-brain barrier [4].

References
1. Bonuccelli G, Di Natale P, Corsolini F, Villani G, Regis S, Filocamo M. (2001) The effect of four mutations on the expression of iduronate-2-sulfatase in mucopolysaccharidosis type II. Biochim Biophys Acta, 1537 (3): 233-8. [PMID:11731225]
2. Demydchuk M, Hill CH, Zhou A, Bunkóczi G, Stein PE, Marchesan D, Deane JE, Read RJ. (2017) Insights into Hunter syndrome from the structure of iduronate-2-sulfatase. Nat Commun, 8: 15786. [PMID:28593992]
3. Okuyama T, Eto Y, Sakai N, Nakamura K, Yamamoto T, Yamaoka M, Ikeda T, So S, Tanizawa K, Sonoda H et al.. (2021) A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II. Mol Ther, 29 (2): 671-679. [PMID:33038326]
4. Sonoda H, Morimoto H, Koshimura Y, Kinoshita M, Takagi H, Yui Y. (2015) Novel anti-transferrin receptor antibody that passes through blood-brain barrier. Patent number: WO2015098989A1. Assignee: JCR Pharmaceuticals. Priority date: 25/12/2013. Publication date: 02/07/2015.
5. Sonoda H, Morimoto H, Yoden E, Koshimura Y, Kinoshita M, Golovina G, Takagi H, Yamamoto R, Minami K, Mizoguchi A et al.. (2018) A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II. Mol Ther, 26 (5): 1366-1374. [PMID:29606503]

References

1. Bonuccelli G, Di Natale P, Corsolini F, Villani G, Regis S, Filocamo M. (2001)
The effect of four mutations on the expression of iduronate-2-sulfatase in mucopolysaccharidosis type II.
Biochim Biophys Acta, 1537 (3): 233-8. [PMID:11731225]

2. Demydchuk M, Hill CH, Zhou A, Bunkóczi G, Stein PE, Marchesan D, Deane JE, Read RJ. (2017)
Insights into Hunter syndrome from the structure of iduronate-2-sulfatase.
Nat Commun, 8: 15786. [PMID:28593992]

3. Okuyama T, Eto Y, Sakai N, Nakamura K, Yamamoto T, Yamaoka M, Ikeda T, So S, Tanizawa K, Sonoda H et al.. (2021)
A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II.
Mol Ther, 29 (2): 671-679. [PMID:33038326]

4. Sonoda H, Morimoto H, Koshimura Y, Kinoshita M, Takagi H, Yui Y. (2015)
Novel anti-transferrin receptor antibody that passes through blood-brain barrier.
Patent number: WO2015098989A1. Assignee: JCR Pharmaceuticals. Priority date: 25/12/2013. Publication date: 02/07/2015.

5. Sonoda H, Morimoto H, Yoden E, Koshimura Y, Kinoshita M, Golovina G, Takagi H, Yamamoto R, Minami K, Mizoguchi A et al.. (2018)
A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
Mol Ther, 26 (5): 1366-1374. [PMID:29606503]